More Apellis Pharmaceuticals, Inc. news Apellis Pharmaceuticals, Inc.NASDAQ: APLS Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN Aug 8, 2024 · Issued by Apellis Pharmaceuticals, Inc. As issuedPlain English Watch Apellis Pharmaceuticals explain it↗Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call · Replay · Feb 24Met the primary endpoint, achieving statistically significant 68% (p
